Chip stocks fall with Nvidia after data center rev disappointment
Peter W. Rodino III, the Chief Operating Officer, Secretary, and General Counsel of AIM ImmunoTech Inc. (AMEX:NYSE:AIM), recently acquired 500 shares of the company’s common stock. The purchase was made on April 4, 2025, at a price of $0.087 per share, amounting to a total transaction value of $43. The purchase comes as the stock trades near its 52-week low of $0.11, having declined about 78% over the past year. According to InvestingPro analysis, the company maintains a weak financial health score of 1.29. Following this acquisition, Rodino’s total direct ownership stands at 401,762 shares. This transaction reflects Rodino’s continued investment in the Ocala, Florida-based biotech firm, despite analysts projecting continued losses for the current fiscal year. Discover more insights about AIM’s valuation and growth prospects with InvestingPro, which offers 10+ additional exclusive tips for this stock.
In other recent news, Aimia reported a strong performance for the fourth quarter of 2024, with a 27% increase in revenue, reaching $127.2 million. The company also managed to reduce its net loss by $17.8 million, bringing it down to $42.1 million. Despite these positive financial results, Aimia missed its earnings per share (EPS) expectations slightly, reporting an actual EPS of -$0.10 compared to the forecast of -$0.09. Looking ahead, Aimia projects its adjusted EBITDA for 2025 to range between $88 million and $95 million, reflecting a 13.8% improvement. Meanwhile, AIM ImmunoTech is facing a delisting from the NYSE American exchange due to a persistently low stock price. The company plans to appeal the decision, though it acknowledges the uncertainty of a successful outcome. AIM ImmunoTech’s stock is set to begin trading on the Pink Open Market, and further details are available in the company’s SEC filings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.